Xiaoli Wang
- Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 32
- Mesenchymal stem cell research 14
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 20
- Acute Myeloid Leukemia Research 14
- Cancer Research top 5%
- MicroRNA in disease regulation 15
- Cancer-related molecular mechanisms research 14
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 10
- Immunology top 5%
-
- Eosinophilic Disorders and Syndromes 11
- Cited by
- GeneticsHematologyCancer Research
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Xiaoli Wang
315 papers receiving 5.2k citations
Peers
Comparison fields: 5 of 162
- Genetics 686
- Hematology 578
- Cancer Research 581
- Oncology 993
- Immunology 733
Countries citing papers authored by Xiaoli Wang
This map shows the geographic impact of Xiaoli Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoli Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoli Wang more than expected).
Fields of papers citing papers by Xiaoli Wang
This network shows the impact of papers produced by Xiaoli Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoli Wang. The network helps show where Xiaoli Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaoli Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 2 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 1 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 10 | |
| 8 | 2023 | 4 | |
| 9 | 2022 | 6 | |
| 10 | 2022 | 4 | |
| 11 | 2021 | 5 | |
| 12 | 2020 | 12 | |
| 13 | 2019 | 29 | |
| 14 | 2018 | 52 | |
| 15 | 2017 | 64 | |
| 16 | 2017 | 8 | |
| 17 | Effect of the matrices and penetration enhancers in elemene transdermal drug delivery system. | 2011 | 4 |
| 18 | 2010 | 22 | |
| 19 | Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion | 2010 | 3 |
| 20 | 2009 | 30 |
About Xiaoli Wang
Xiaoli Wang is a scholar working on Genetics, Hematology, Cancer Research, Oncology and Immunology, having authored 334 papers that have together received 5.3k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Chronic Myeloid Leukemia Treatments (20 papers), MicroRNA in disease regulation (15 papers), Acute Myeloid Leukemia Research (14 papers), Cancer-related molecular mechanisms research (14 papers), Mesenchymal stem cell research (14 papers), Eosinophilic Disorders and Syndromes (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). The work is most often cited by research in Genetics (686 citations), Hematology (578 citations), Cancer Research (581 citations), Oncology (993 citations) and Immunology (733 citations). Xiaoli Wang has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Ronald Hoffman, Jun Ren, Xinna Zhou, Min Lü, H. Kim Lyerly, Yijun Luo, Chi Li, Mingjiang Xu, Yanhui Zhang and Huilu Wu. Their work appears in journals such as Blood, Stem Cells, Medicine, Scientific Reports and Transplantation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.